Secondary Occult Hepatitis C Virus Infection (HCV) in Chronic HCV Patients after Treatment with Sofosbuvir and Daclatasvir

Nashwa A. Abu Khadr; Hanan H. Nouh; Nesrine F. Hanafi; Sara L. Asser; Yousra A. Hussain

doi:https://doi.org/10.20546/ijcmas.2018.701.165

Login as a Reviewer

Indexed in

National Academy of Agricultural Sciences (NAAS)

NAAS Score: *5.38 (2020)

[Effective from January 1, 2020]
For more details click here

ICV 2022: 95.28

Index Copernicus ICI Journals Master List 2022 - IJCMAS--ICV 2022: 95.28
For more details click here

Announcement

Volume-13, Issue-3 Published

Call for paper-Vol-13, Issue 4- April 2024

See Guidelines to Authors
Current Issues

Download Publication Certificate

Original Research Articles Volume : 7, Issue:1, January, 2018

PRINT ISSN : 2319-7692
Online ISSN : 2319-7706
Issues : 12 per year
Publisher : Excellent Publishers
Email : editorijcmas@gmail.com /
submit@ijcmas.com
Editor-in-chief: Dr.M.Prakash
Index Copernicus ICV 2018: 95.39
NAAS RATING 2020: 5.38

Metrics and citations

Int.J.Curr.Microbiol.App.Sci.2018.7(1): 1357-1365

DOI: https://doi.org/10.20546/ijcmas.2018.701.165

Secondary Occult Hepatitis C Virus Infection (HCV) in Chronic HCV Patients after Treatment with Sofosbuvir and Daclatasvir

Nashwa A. Abu Khadr¹, Hanan H. Nouh², Nesrine F. Hanafi¹, Sara L. Asser¹ and Yousra A. Hussain^1*

¹Department of Microbiology, Faculty of Medicine, Alexandria University, Alexandria, Egypt
²Department of Internal Medicine, Gastroenterology unit, Faculty of Medicine, Alexandria University, Alexandria, Egypt

^*Corresponding author

Abstract:

This study is a cross-sectional study aimed to assess the rate of occurrence of secondary occult hepatitis C virus (HCV) infection in patients treated with the combination of sofosbuvir and daclatasvir. This study included 40 patients whose serum turned negative for HCV ribonucleic acid (HCV RNA) via real time polymerase chain reaction (RT-PCR) after 3 months of the treatment. Blood samples on EDTA were collected from the patients to detect HCV RNA in peripheral blood mononuclear cells (PBMCs). At the end of the study there were 30 PBMCs HCV RNA negative patients and 10 PBMCs HCV RNA positive patients. Our data revealed the occurrence of secondary occult HCV infection in about 25% of HCV patients treated with the combination of sofosbuvir and daclatasvir.

Keywords: Occult HCV, Peripheral blood mononuclear cells, Sofosbuvir, Daclatasvir, Direct acting antiviral drugs

Download this article as

How to cite this article:

Nashwa A. Abu Khadr, Hanan H. Nouh, Nesrine F. Hanafi, Sara L. Asser and Yousra A. Hussain. 2018. Secondary Occult Hepatitis C Virus Infection (HCV) in Chronic HCV Patients after Treatment with Sofosbuvir and Daclatasvir.Int.J.Curr.Microbiol.App.Sci. 7(1): 1357-1365. doi: https://doi.org/10.20546/ijcmas.2018.701.165

Copyright: This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike license.

Citations

Scroll

Join as a Reviewer

Login as a Reviewer

Original Research Articles Volume : 7, Issue:1, January, 2018

How to cite this article:

Citations